Seung Ki Min
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Seung Ki Min has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Byung Joo Chae
Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication Dong Wook Choi
Department of Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea
1 shared publicationEun Jin Kim
Theracion Biomedical Co., Ltd, Seongnam, Gyeonggi 13207, South Korea
1 shared publicationHyun Kyoon Kim
Theracion Biomedical Co., Ltd, Seongnam, Gyeonggi 13207, South Korea
1 shared publication- In Woong Han
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul South Korea
1 shared publication - Jai Min Ryu
Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Clinical Evaluation of the Hemostatic Efficacy and Safety of a Biodegradable Hemostatic Agent, Hemogram: A Comparative Study with Arista™ AH
Background: Hemogram is a novel biodegradable powdered hemostatic agent developed by binding calcium ions (Ca² + ) to carboxymethyl starch (CM-starch) and applying granulation technology to enhance blood absorption and hemostatic efficacy. This study aimed to evaluate the clinical efficacy and safety of Hemogram compared with the commercially available agent Arista™ AH in patients undergoing gastrectomy. Methods: This randomized controlled trial was conducted at Samsung Medical Center and included patients who experienced intraoperative oozing-type bleeding during gastrectomy. A total of 64 patients were enrolled and evenly randomized to receive either Hemogram (n = 32) or Arista™ AH (n = 32) for local hemostasis. The primary efficacy endpoint was the hemostatic success rate within 5 min. Secondary endpoints included hemostasis time, re-bleeding rate, number of hemostatic agent units used, transfusion volume, length of hospital stay, and incidence of adverse events. Results: Hemostatic success within 5 min was achieved in 100% (32/32) of the Hemogram group and 96.9% (31/32) of the Arista™ AH group, with no statistically significant difference between the two (P > 0.05). The mean time to hemostasis was 1.25 ± 0.80 min in the Hemogram group and 1.52 ± 0.85 min in the Arista™ AH group. No re-bleeding events were observed in the Hemogram group, while one case of re-bleeding (3.3%) was reported in the Arista™ AH group. There were no significant differences between groups in terms of transfusion volume, length of hospitalization, or adverse event rates. Conclusion: Hemogram demonstrated non-inferior hemostatic efficacy and safety compared to Arista™ AH in patients undergoing gastrectomy. These findings suggest that Hemogram is a promising and clinically applicable hemostatic agent for surgical use.
- 16 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessClinical Evaluation of the Hemostatic Efficacy and Safety of a Biodegradable Hemostatic Agent, Hemogram: A Comparative Study with Arista™ AH
Background: Hemogram is a novel biodegradable powdered hemostatic agent developed by binding calcium ions (Ca² + ) to carboxymethyl starch (CM-starch) and applying granulation technology to enhance blood absorption and hemostatic efficacy. This study aimed to evaluate the clinical efficacy and safety of Hemogram compared with the commercially available agent Arista™ AH in patients undergoing gastrectomy. Methods: This randomized controlled trial was conducted at Samsung Medical Center and included patients who experienced intraoperative oozing-type bleeding during gastrectomy. A total of 64 patients were enrolled and evenly randomized to receive either Hemogram (n = 32) or Arista™ AH (n = 32) for local hemostasis. The primary efficacy endpoint was the hemostatic success rate within 5 min. Secondary endpoints included hemostasis time, re-bleeding rate, number of hemostatic agent units used, transfusion volume, length of hospital stay, and incidence of adverse events. Results: Hemostatic success within 5 min was achieved in 100% (32/32) of the Hemogram group and 96.9% (31/32) of the Arista™ AH group, with no statistically significant difference between the two (P > 0.05). The mean time to hemostasis was 1.25 ± 0.80 min in the Hemogram group and 1.52 ± 0.85 min in the Arista™ AH group. No re-bleeding events were observed in the Hemogram group, while one case of re-bleeding (3.3%) was reported in the Arista™ AH group. There were no significant differences between groups in terms of transfusion volume, length of hospitalization, or adverse event rates. Conclusion: Hemogram demonstrated non-inferior hemostatic efficacy and safety compared to Arista™ AH in patients undergoing gastrectomy. These findings suggest that Hemogram is a promising and clinically applicable hemostatic agent for surgical use.
- 22 May 2022
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (9) , 1004-1013
Prognosis of pancreatic head cancer with different patterns of lymph node metastasis
Background: The nodal stage of pancreatic ductal adenocarcinoma (PDAC) is revised in the AJCC 8th edition. Studies on the prognosis of PDAC according to lymph node metastasis (LNM) are still ongoing. We attempted to find the patterns of nodal involvement and to reveal its clinical significance to overall survival (OS).Methods: We analyzed 585 patients who received pancreatic head cancer surgery diagnosed as PDAC from January 2007 to December 2016. Patients were classified into three groups: Group 1 (G1, patients without LNM), Group 2 (G2, those with LNM only in the peripancreatic area), and Group 3 (G3 those with LNM in the other area and/or peripancreatic LNM). Risk factors were analyzed by Cox‐regression test and overall survival was compared by Kaplan–Meier analysis.Results: LNM in peripancreatic area was the most common (88.7%). In the multivariate analysis, T stage, nuclear differentiation, adjuvant treatment, and the G2 and G3 were independent risk factors for OS (G2 over G1, HR 1.384, 95% CI 1.046–1.802; P = .036 and G3 over G1, HR 2.383, 95% CI 1.378–4.103; P = .001). G3 showed worse OS than G2 (P = .006). In the N1 status, LNM to the pericholedochal (PC) and superior mesenteric artery (SMA) areas resulted in worse OS than the G2 (P = .011 and P = .019).Conclusions: We found that LNM beyond the peripancreatic area significantly affects OS in pancreatic head cancer patients. Depending on the station of the LNM, different risk‐stratification and treatment strategies will need to be considered.
- 22 May 2022
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (9) , 1004-1013
Prognosis of pancreatic head cancer with different patterns of lymph node metastasis
Background: The nodal stage of pancreatic ductal adenocarcinoma (PDAC) is revised in the AJCC 8th edition. Studies on the prognosis of PDAC according to lymph node metastasis (LNM) are still ongoing. We attempted to find the patterns of nodal involvement and to reveal its clinical significance to overall survival (OS).Methods: We analyzed 585 patients who received pancreatic head cancer surgery diagnosed as PDAC from January 2007 to December 2016. Patients were classified into three groups: Group 1 (G1, patients without LNM), Group 2 (G2, those with LNM only in the peripancreatic area), and Group 3 (G3 those with LNM in the other area and/or peripancreatic LNM). Risk factors were analyzed by Cox‐regression test and overall survival was compared by Kaplan–Meier analysis.Results: LNM in peripancreatic area was the most common (88.7%). In the multivariate analysis, T stage, nuclear differentiation, adjuvant treatment, and the G2 and G3 were independent risk factors for OS (G2 over G1, HR 1.384, 95% CI 1.046–1.802; P = .036 and G3 over G1, HR 2.383, 95% CI 1.378–4.103; P = .001). G3 showed worse OS than G2 (P = .006). In the N1 status, LNM to the pericholedochal (PC) and superior mesenteric artery (SMA) areas resulted in worse OS than the G2 (P = .011 and P = .019).Conclusions: We found that LNM beyond the peripancreatic area significantly affects OS in pancreatic head cancer patients. Depending on the station of the LNM, different risk‐stratification and treatment strategies will need to be considered.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Breast Cancer
- Vol. 24 (1) , 75-84
Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer
Min SK, et al. J Breast Cancer. 2020 Sep;24:e4. https://doi.org/10.4048/jbc.2021.24.e4
- 1 January 2021
- Published by XMLink in Journal of Breast Cancer
- Vol. 24 (1) , 75-84
Open AccessRelation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer
Min SK, et al. J Breast Cancer. 2020 Sep;24:e4. https://doi.org/10.4048/jbc.2021.24.e4